Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells

Liu,Xuchun; Sun,Gengyun

doi:10.3892/ol.2017.6702

Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells

Authors:
- Xuchun Liu
- Gengyun Sun
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: August 2, 2017 https://doi.org/10.3892/ol.2017.6702
Pages: 4270-4276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Shikonin (SHK) is a natural naphthoquinone pigment isolated from Lithospermum erythrorhizon, that has been reported to suppress the growth of a number of cancer cell types. Adriamycin (AD) is typically used as an effective anticancer agent; however, it has the propensity to induce drug resistance. The aim of the present study was to investigate the effects of SHK alone and in combination with AD on lung adenocarcinoma cells and the underlying molecular mechanisms of their effects. Colony formation, MTT and propidium iodide staining assays demonstrated that the co‑treatment of A549 cells with SHK and AD significantly decreased cell viability and potently induced apoptosis. The mitochondrial membrane potential was assessed using 5,5', 6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide staining and fluorescence microscopy. Cells co‑treated with SHK and AD exhibited marked mitochondrial membrane damage. In addition, co‑treatment with SHK and AD significantly reduced ATP levels in A549 cells compared with the control. Western blot analysis revealed that SHK enhanced the antitumor effects of AD by inhibiting the expression of ATP‑binding cassette transporters. These results suggest that the inhibition of glycolysis could be an effective approach for lung cancer treatment. Therefore, SHK has the potential to be used as an anticancer agent in the treatment of lung adenocarcinoma, and thus warrants further investigation and development.

View Figures

View References

1	Alberg AJ, Ford JG and Samet JM: American College of Chest Physicians: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132:(3 Suppl). 29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI
2	Baltayiannis N, Chandrinos M, Anagnostopoulos D, Zarogoulidis P, Tsakiridis K, Mpakas A, Machairiotis N, Katsikogiannis N, Kougioumtzi I, Courcoutsakis N and Zarogoulidis K: Lung cancer surgery: An up to date. J Thorac Dis. 5:(Suppl 4). S425–S439. 2013.PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN and Thun MJ: Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 97:(12 Suppl). S3133–S3275. 2003. View Article : Google Scholar
5	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
6	Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D and McCusker ME: Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. PLoS One. 12:e01756792017. View Article : Google Scholar : PubMed/NCBI
7	Yoon SM, Shaikh T and Hallman M: Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 8:1–20. 2017. View Article : Google Scholar : PubMed/NCBI
8	Galvani E, Peters GJ and Giovannetti E: EGF receptor-targeted therapy in non-small-cell lung cancer: Role of germline polymorphisms in outcome and toxicity. Future Oncol. 8:1015–1029. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bach DH, Hong JY, Park HJ and Lee SK: The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer. 141:220–230. 2017. View Article : Google Scholar : PubMed/NCBI
10	Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
11	Allen JD and Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 1:427–434. 2002.PubMed/NCBI
12	Oshikata A, Matsushita T and Ueoka R: Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng. 111:590–593. 2011. View Article : Google Scholar : PubMed/NCBI
13	Joyce H, McCann A, Clynes M and Larkin A: Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Exp Opin Drug Metab Toxicol. 11:795–809. 2015. View Article : Google Scholar
14	El-Sheikh AA, Morsy MA, Mahmoud MM and Rifaai RA: Protective mechanisms of coenzyme-Q10 may involve up-regulation of testicular P-glycoprotein in doxorubicin-induced toxicity. Environ Toxicol Pharmacol. 37:772–781. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ponnusamy L, Mahalingaiah PKS and Singh KP: Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells. Eur J Pharm Sci. 104:424–433. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wang CY, Bai XY and Wang CH: Traditional chinese medicine: A treasured natural resource of anticancer drug research and development. Am J Chin Med. 42:543–559. 2014. View Article : Google Scholar : PubMed/NCBI
17	Liu Z, Chen S, Cai J, Zhang E, Lan L, Zheng J, Liao L, Yang X, Zhou C and Du J: Traditional Chinese medicine syndrome-related herbal prescriptions in treatment of malignant tumors. J Tradit Chin Med. 33:19–26. 2013. View Article : Google Scholar : PubMed/NCBI
18	Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J and Hu X: Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 6:1641–1649. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009. View Article : Google Scholar : PubMed/NCBI
20	Xuan Y and Hu X: Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett. 274:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
21	Bailly C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem. 7:39–58. 2000. View Article : Google Scholar : PubMed/NCBI
22	Nakaya K and Miyasaka T: A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs. 14:683–693. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kim SH, Kang IC, Yoon TJ, Park YM, Kang KS, Song GY and Ahn BZ: Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett. 172:171–175. 2001. View Article : Google Scholar : PubMed/NCBI
24	Chang IC, Huang YJ, Chiang TI, Yeh CW and Hsu LS: Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol Pharm Bull. 33:816–824. 2010. View Article : Google Scholar : PubMed/NCBI
25	Long S, GuangZhi Y, BaoJie G, Wei X, YanYong H, YingLi W, Yang Z and LiHua L: Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice. Phytother Res. 26:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wu H, Xie J, Pan Q, Wang B, Hu D and Hu X: Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PLoS One. 8:e527062013. View Article : Google Scholar : PubMed/NCBI
27	EI Sayed SM, Mahmoud AA, EI Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, Hashim MS, Hemdan SB, Kadry ZM, Abdelmoaty MA, et al: Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses. 81:866–870. 2013. View Article : Google Scholar : PubMed/NCBI
28	Carraro M and Bernardi P: Calcium and reactive oxygen species in regulation of the mitochondrial permeability transition and of programmed cell death in yeast. Cell Calcium. 60:102–107. 2016. View Article : Google Scholar : PubMed/NCBI
29	Padmapriya R, Gayathri L, Ronsard L, Akbarsha MA and Raveendran R: In vitro anti-proliferative effect of tephrosia purpurea on human hepatocellular carcinoma cells. Pharmacogn Mag. 13:(Suppl 1). S16–S21. 2017. View Article : Google Scholar : PubMed/NCBI
30	Falasca M and Linton KJ: Investigational ABC transporter inhibitors. Expert Opin Invest Drugs. 21:657–666. 2012. View Article : Google Scholar
31	Joyce H, McCann A, Clynes M and Larkin A: Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol. 11:795–809. 2015. View Article : Google Scholar : PubMed/NCBI
32	Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
33	Pavan B, Paganetto G, Rossi D and Dalpiaz A: Multidrug resistance in cancer or inefficacy of neuroactive agents: Innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discov Today. 19:1563–1571. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ponisovskiy MR: Warburg effect mechanism as the target for theoretical substantiation of a new potential cancer treatment. Crit Rev Eukaryot Gene Expr. 21:13–28. 2011. View Article : Google Scholar : PubMed/NCBI
35	Bayley JP and Devilee P: The Warburg effect in 2012. Curr Opin Oncol. 24:62–67. 2012. View Article : Google Scholar : PubMed/NCBI
36	Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
37	Sotgia F, Martinez-Outschoorn UE and Lisanti MP: Genetic induction of the Warburg effect inhibits tumor growth. Oncotarget. 3:1266–1267. 2012. View Article : Google Scholar : PubMed/NCBI
38	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
39	Granchi C and Minutolo F: Anticancer agents that counteract tumor glycolysis. ChemMedChem. 7:1318–1350. 2012. View Article : Google Scholar : PubMed/NCBI
40	Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K and Fujiwara Y: Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 99:9–17. 2006. View Article : Google Scholar : PubMed/NCBI
41	Kovalev AA, Tsvetaeva DA and Grudinskaja TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 35:287–290. 2013.PubMed/NCBI
42	Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, et al: Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 10:117–125. 2011. View Article : Google Scholar : PubMed/NCBI
43	Nambaru PK, Hübner T, Köck K, Mews S, Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C, et al: Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos. 39:132–139. 2011. View Article : Google Scholar : PubMed/NCBI
44	Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev. 55:3–29. 2003. View Article : Google Scholar : PubMed/NCBI
45	Gao H, Lamusta J, Zhang WF, Salmonsen R, Liu Y, O'Connell E, Evans JE, Burstein S and Chen JJ: Tumor cell selective cytotoxicity and apoptosis induction by an herbal preparation from Brucea javanica. N Am J Med Sci (Boston). 4:62–66. 2011. View Article : Google Scholar : PubMed/NCBI
46	Yeh YC, Liu TJ and Lai HC: Shikonin induces apoptosis, necrosis, and premature senescence of human A549 lung cancer cells through upregulation of p53 expression. Evid Based Complement Alternat Med. 2015:6203832015. View Article : Google Scholar : PubMed/NCBI